

In the claims:

For the convenience of the Examiner, all claims being examined, whether or not amended, are presented below.

1-50. **(Cancelled)**

51. **(Currently amended)** A purified preparation of an antibody, or an antigen binding domain thereof, which is specifically binds to ~~immunoreactive with~~ a mammalian RAPT1 protein and does not substantially cross react with a fungal TOR1 or TOR2 protein.
52. **(Currently amended)** A polyclonal antibody preparation enriched for antibodies which specifically ~~immunoreactive with~~ bind to a mammalian RAPT1 protein.
53. **(Currently amended)** A monoclonal antibody composition including a monoclonal antibody, or an antigen binding domain thereof, which is specifically binds to ~~immunoreactive with~~ a mammalian RAPT1 protein and does not substantially cross react with a fungal TOR1 or TOR2 protein.
54. **(Currently amended)** A recombinant antibody including an antigen binding domain which is specifically binds to ~~immunoreactive with~~ a mammalian RAPT1 protein and does not substantially cross react with a fungal TOR1 or TOR2 protein.
55. **(Currently amended)** The preparation of claim 51, wherein the antibody binds to ~~is~~ ~~immunoreactive with~~ a RAPT1 protein having an amino acid sequence at least 90 percent identical to the sequence of SEQ ID No. 12.
56. **(Previously added)** The preparation of claim 55, wherein the antibody has a binding affinity of less than 10 percent for a yeast TOR1 or TOR2 protein.

57. **(Currently amended)** The preparation of claim 52, enriched for antibodies immunoreactive with which bind to a RAPT1 protein having an amino acid sequence at least 90 percent identical to the sequence of SEQ ID No. 12.
58. **(Previously added)** The preparation of claim 57 wherein the preparation has a binding affinity of less than 10 percent for a yeast TOR1 or TOR2 protein.
59. **(Currently amended)** The preparation of claim 53, wherein the monoclonal antibody binds to is immunoreactive with a RAPT1 protein having an amino acid sequence at least 90 percent identical to the sequence of SEQ ID No. 12.
60. **(Previously added)** The preparation of claim 59, wherein the antibody has a binding affinity of less than 10 percent for a yeast TOR1 or TOR2 protein.
61. **(Currently amended)** The preparation of claim 54, wherein the antigen binding domain binds to is immunoreactive with a RAPT1 protein having an amino acid sequence at least 90 percent identical to the sequence of SEQ ID No. 12.
62. **(Previously added)** The preparation of claim 61, wherein the antibody has a binding affinity of less than 10 percent for a yeast TOR1 or TOR2 protein.